





Form PTO-1449 (Rev. 3-03)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 01681/2/US		Application Number 10/626,166	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				First Named Inventor Amidon, et al.			
				Filing Date July 24, 2003		Group Art Unit Unknown	
U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date If Appropriate
9/1		US 5,458,887	Oct 17, 1995	Chen et al.	424	464	
		US 5,656,296	Aug 12, 1997	Khan et al.	424	473	
		US 6,197,339	Mar 06, 2001	Ju	424	468	
FOREIGN PATENT DOCUMENTS							
Examiner Initial*		Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Translation Yes No
		EP 0 933 079	Aug 4, 1999	Cerestar Holding BV	A61K	9/20	
OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)							
		Hiestand & Smith, (1984), <i>Powder Technology</i> , 38, pp. 145-159					
		Hiestand & Smith, (1991), <i>International Journal of Pharmaceutics</i> , 67, pp. 231-246					
		Physicians' Desk Reference, 57 th ed. (2003), pp. 2768-2772					
Examiner	Date Considered						
9/1	8/31/2006						
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									ATTY. DOCKET NO. PC28053			SERIAL NO. 10/626,166		
									APPLICANT Amidon et al.					
									FILING DATE July 25, 2002			GROUP 1614		
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
9n	a)	6	2	7	7	8	7	5	8/21/01	Holman, Andrew J.	514	367		
	b)	4	7	3	1	3	7	4	3/15/88	Griss et al.	514	367		
	c)	0	0	1	5	7	3	5	2/7/02	Hedden et al.	424	488		
	d)	6	0	5	6	9	7	7	5/2/00	Bhagwat et al.	424	488		
	e)	5	4	7	2	7	1	2	12/5/95	Oshlack et al.	424	480		
	f)	6	1	9	7	3	3	9	3/6/01	Ju, Tzu-chi Robert	424	468		
	g)	5	4	5	8	8	8	7	10/17/95	Chen et al.	424	464		
	h)	5	6	5	6	2	9	6	8/12/97	Khan et al.	424	473		
	i)	2	8	8	7	4	4	0	5/19/59	Greminger et al.	167	82		
	FOREIGN PATENT DOCUMENTS													
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	j)	0	1	2	2	8	2	0	4/5/01	WO	A01N	43/78		
	k)	9	9	1	6	4	4	2	4/8/99	WO	A61K			
	l)	9	9	0	9	0	6	6	2/25/99	WO	C08B	A61K		
	m)	9	9	4	5	9	2	4	9/16/99	WO	A61K			
	n)	0	9	3	3	0	7	9	1/26/99	EPC	A61K	C08B		
	o)	0	0	5	9	4	7	7	10/12/00	WO	A61K			
	p)	9	7	0	4	7	5	2	2/13/97	WO	A61K			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
	q)	Physicians' Desk Reference 57th edition (2003), 2768-2772												
	r)	Hiestand & Smith (1984), Powder Technology 38, 145-159												
	s)	Hiestand & Smith (1991), International Journal of Pharmaceutics 67, 231-246												
	t)	Hubble et al. (1995), Clinical Neuropharmacology 18(4), 338-347												
	u)	Dooley & Markham (1998), Drugs & Aging 12(6), 495-514												
9n	v)	Biglan & Holloway (2002), Expert Opinion on Pharmacotherapy 3(2), 197-210												

9n 8/31/2006



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC28053	SERIAL NO. 10/626,166
		APPLICANT Amidon et al.	
		FILING DATE July 25, 2002	GROUP 1614
JA	w)	Wright et al. (1997), <i>Journal of Clinical Pharmacology</i> 37, 520-525	
JA	x)	United States Pharmacopeia 24th edition (2000) (USP 24), pp. 1941-1943	
CA	y)	Colosimo & De Michele (1999), <i>European Journal of Neurology</i> 6(1), 1-21	
EXAMINER		DATE CONSIDERED	
A. Noy		8/31/2006	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE